Cantor Fitzgerald Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $104
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $75
Viking Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $104
Viking Therapeutics Analyst Ratings
Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $71 to $118
Viking Therapeutics Price Target Cut to $102.00/Share From $105.00 by Morgan Stanley
Viking Therapeutics Is Maintained at Overweight by Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Edwards Lifesciences (EW) and Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
William Blair Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Promising Developments and Financial Stability Underpin Buy Rating for Viking Therapeutics
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $100
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $100
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Viking Therapeutics Analyst Ratings
Viking Therapeutics' VK2735 Gains Buy Rating Amid Pfizer's GLP-1 Drug Halt and Promising Trial Results
Goldman Sachs Maintains Viking Therapeutics(VKTX.US) With Hold Rating, Maintains Target Price $30